All In Biotech

Drug Trial Radar · NCT03821935

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 364 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

364

Actual

Start

Feb 21, 2019

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jan 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.

Conditions

  • Advanced Solid Tumors Cancer

Interventions

  • LivmoniplimabDrug

    Liquid for intravenous infusion.

  • BudigalimabDrug

    Lyophilized powder for solution for intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Recommended Phase 2 Dose (RP2D) Livmoniplimab MonotherapyTime frame: Up to 28 days after the first dose of Livmoniplimab monotherapy
  2. Dose Escalation: RP2D Livmoniplimab + Budigalimab Combination TherapyTime frame: Up to 28 days after the first dose of Livmoniplimab and Budigalimab combination therapy
  3. Dose Expansion: Objective Response Rate (ORR)Time frame: Up to approximately 6 months after the first dose date of last participant in Dose Expansion

Locations

64 sites in 14 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group, PA /ID# 218942

    Springdale, Arkansas

  • City of Hope National Medical Center /ID# 265620

    Duarte, California

  • City of Hope Orange County Lennar Foundation Cancer Center /ID# 270785

    Irvine, California

  • Yale University School of Medicine /ID# 208356

    New Haven, Connecticut

  • AdventHealth Celebration /ID# 224860

    Celebration, Florida

  • Duplicate_AdventHealth Cancer Institute - Orlando /ID# 226953

    Orlando, Florida

  • Indiana Univ School Medicine /ID# 208384

    Indianapolis, Indiana

  • Community Health Network, Inc. /ID# 257032

    Indianapolis, Indiana

  • Univ Michigan Med Ctr /ID# 221129

    Ann Arbor, Michigan

  • Washington University-School of Medicine /ID# 259684

    St Louis, Missouri

  • Intermountain Health West End Clinic Gynecologic Oncology /ID# 266171

    Billings, Montana

  • NYU Langone Medical Center /ID# 209822

    New York, New York

  • Icahn School of Medicine at Mount Sinai /ID# 264653

    New York, New York

  • Carolina BioOncology Institute /ID# 208358

    Huntersville, North Carolina

  • The Ohio State University - The James /ID# 217611

    Columbus, Ohio

  • Ou Health - Stephenson Cancer Center /ID# 268826

    Oklahoma City, Oklahoma

  • Sarah Cannon Research Institute (SMO/Network/Consortium) /ID# 264900

    Nashville, Tennessee

  • Renovatio clinical /ID# 265109

    El Paso, Texas

  • NEXT Oncology /ID# 208930

    San Antonio, Texas

  • Renovatio Clinical /ID# 265054

    The Woodlands, Texas

  • University of Washington Medical Center /ID# 268854

    Seattle, Washington

  • Chris O'Brien Lifehouse /ID# 213236

    Camperdown, New South Wales, Australia

  • Icon Cancer Centre /ID# 224961

    South Brisbane, Queensland, Australia

  • Cliniques Universitaires UCL Saint-Luc /ID# 218466

    Brussels, Brussels Capital, Belgium

  • University Health Network_Princess Margaret Cancer Centre /ID# 209423

    Toronto, Ontario, Canada

  • Centre Jean Perrin /ID# 218669

    Clermont-Ferrand, France

  • CHU Toulouse - Hopital Purpan /ID# 218667

    Toulouse, Haute-Garonne, France

  • Centre Leon Berard /ID# 218515

    Lyon, Rhone, France

  • Institut Gustave Roussy /ID# 218668

    Villejuif, Val-de-Marne, France

  • Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung /ID# 269587

    Essen, North Rhine-Westphalia, Germany

  • Hadassah Medical Center-Hebrew University /ID# 257918

    Jerusalem, Israel

  • Rabin Medical Center /ID# 258479

    Petah Tikva, Israel

  • Rambam Health Care Campus /ID# 222198

    Haifa, H_efa, Israel

  • The Chaim Sheba Medical Center /ID# 209037

    Ramat Gan, Tel Aviv, Israel

  • Tel Aviv Sourasky Medical Center /ID# 222199

    Tel Aviv, Tel Aviv, Israel

  • Istituto Europeo Di Oncologia /Id# 266053

    Milan, Milano, Italy

  • National Cancer Center Hospital East /ID# 224808

    Kashiwa-shi, Chiba, Japan

  • Hyogo Cancer Center /ID# 272553

    Akashi-shi, Hyōgo, Japan

  • National Cancer Center Hospital /ID# 209421

    Chuo-ku, Tokyo, Japan

  • Jagiellonskie Centrum Innowacji Sp. z o.o. /ID# 266194

    Krakow, Lesser Poland Voivodeship, Poland

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.